GlassScriptPhysician profile
Jerome A Dixon
NPI 1215919451
$3,694.49
in general payments reported to CMS, 2019-2025
44 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $706 · 2021: $656 · 2022: $712 · 2023: $466 · 2024: $390 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $300.00 | 2020 | |
| Lilly USA, LLC | $298.05 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $264.99 | 2019-2024 | Repatha, Otezla, Evenity |
| Abbvie INC. | $254.66 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $226.71 | 2019-2024 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $212.90 | 2019-2023 | |
| Pfizer INC. | $197.43 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.15 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.02 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Indivior INC. | $118.64 | 2019-2025 | Sublocade |
| Sanofi-Aventis U.S. LLC | $117.50 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.10 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $105.10 | 2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $104.62 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $103.46 | 2020-2023 | Austedo Xr |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.